Herbert H F Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, discusses the efficacy of D3S-001 in pretreated NSCLC.
Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO
Advertisement
Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO, is a clinical associate professor in the Department of Clinical Oncology and the deputy medical director of the Phase 1 Clinical Trials Centre at The Chinese University of Hong Kong; as well as an honorary consultant in the Department of Clinical Oncology at the Prince of Wales Hospital/New Territories East Cluster, Hospital Authority
Articles by Herbert H F Loong, MBBS, PDipMDPath, MRCP, FRCP Edin, FHKCP, FHKAM(Medicine), FASCO
Advertisement
Latest Updated Articles
Dr Loong on the Efficacy of D3S-001 in KRAS G12C Inhibitor–Resistant NSCLCPublished: April 30th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
5